PARP1 and prostate carcinoma: The early diagnosis of BRCA2 mutations is important because these mutations have been associated with earlier onset and highly aggressive prostate cancers with poorer outcomes and with a higher sensitivity to PARP inhibitors and platinum-based chemotherapies.